The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer-Reference-Cited by-同舟云学术

The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer

Published:2015-06 Issue:6 Volume:4 Page:e156-e156
ISSN:2157-9024
Container-title:Oncogenesis
language:en
Short-container-title:Oncogenesis

Author:

Hait N C,Avni D,Yamada A,Nagahashi M,Aoyagi T,Aoki H,Dumur C I,Zelenko Z,Gallagher E J,Leroith D,Milstien S,Takabe K,Spiegel S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology

Link

http://www.nature.com/articles/oncsis201516.pdf

Reference58 articles.

1. Clarke R, Leonessa F, Welch JN, Skaar TC . Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001; 53: 25–71.

2. McDonnell DP, Norris JD . Connections and regulation of the human estrogen receptor. Science 2002; 296: 1642–1644.

3. Bayraktar S, Gluck S . Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 2013; 138: 21–35.

4. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 454–463.

5. Pierobon M, Frankenfeld CL . Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 137: 307–314.

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FTY720/Fingolimod mitigates paclitaxel‐induced Sparcl1‐driven neuropathic pain and breast cancer progression;The FASEB Journal;2024-08-10

2. Regulation of cellular and systemic sphingolipid homeostasis;Nature Reviews Molecular Cell Biology;2024-06-18

3. Self-activating chitosan-based nanoparticles for sphingosin-1 phosphate modulator delivery and selective tumor therapy;International Journal of Biological Macromolecules;2024-06

4. PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives;Biomedicine & Pharmacotherapy;2024-04

5. Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer;International Journal of Molecular Sciences;2024-03-15